<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Skin and Venereal Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Skin and Venereal Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский журнал кожных и венерических болезней</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1560-9588</issn><issn publication-format="electronic">2412-9097</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">37340</article-id><article-id pub-id-type="doi">10.18821/1560-9588-2018-21-2-90-93</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">PATHOGENIC ROLE OF CYTOKINES IN PSORIASIS</article-title><trans-title-group xml:lang="ru"><trans-title>ПАТОГЕНЕТИЧЕСКАЯ РОЛЬ ЦИТОКИНОВ ПРИ ПСОРИАЗЕ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Karapetyan</surname><given-names>Sh. V</given-names></name><name xml:lang="ru"><surname>Карапетян</surname><given-names>Ш. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Khachikyan</surname><given-names>Khachik M.</given-names></name><name xml:lang="ru"><surname>Хачикян</surname><given-names>Хачик Мартынович</given-names></name></name-alternatives><bio xml:lang="en"><p>MD, PhD, DSc., head of department of dermatovenereology and cosmetology Erevan State Medical University n.a. M. Heratsi, Yerevan, 0025, Republic of Armenia</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, профессор, заведующий кафедрой дерматовенерологии и косметологии Ереванского государственного медицинского университета им. М. Гераци МОН РА, 0025, г. Ереван, Республика Армения</p></bio><email>xxm666699@mail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Erevan State Medical University n.a. M. Heratsi</institution></aff><aff><institution xml:lang="ru">Ереванский государственный медицинский университет им. М. Гераци МОН РА</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2018</year></pub-date><volume>21</volume><issue>2</issue><issue-title xml:lang="en">VOL 21, NO2 (2018)</issue-title><issue-title xml:lang="ru">ТОМ 21, №2 (2018)</issue-title><fpage>90</fpage><lpage>93</lpage><history><date date-type="received" iso-8601-date="2020-07-21"><day>21</day><month>07</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, ООО "Эко-Вектор"</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">ООО "Эко-Вектор"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://rjsvd.com/1560-9588/article/view/37340">https://rjsvd.com/1560-9588/article/view/37340</self-uri><abstract xml:lang="en"><p>Aim. The aim of this study is determination of the role of certain pro-inflammatory and anti-inflammatory cytokines in the pathogenesis of psoriasis. Material and methods. The 110 patients with plaque form of psoriasis of moderate severity were examined, who were divided into 2 groups. Group 1 includes 65 patients (43 men and 22 women) from 18 to 64 years old with a duration of disease from 1 year to 39 years. The traditional treatment (detoxification, antioxidant, antihistamine, multivitamin, membrane stabilizing, local anti-inflammatory) was prescribed to the patients of group 1. Group 2 includes 45 patients from 18 to 65 years old (31 men and 14 women) with a duration of disease from 6 months to 32 years. The alternative treatment (with traditional therapy, the hepatoprotectors was also used) was prescribed to the patients of group 2. The control group makes 18 practically healthy periodic donors (9 men and 9 women) from 19 to 57 years old. The level of IFNγ, TNFα, IL-1α, IL-2, IL-10 and TGFβ was investigated in the serum of psoriatic patients by ELISA (commercial kits of Demeditec Diagnostics GmbH were used). Results. Before the treatment, the significant increase of level of circulating pro-inflammatory cytokines and significant decrease of level of anti-inflammatory cytokines were seen in both groups of patients with psoriasis compared with the control group. After the treatment, the level of proinflammatory cytokines is significantly reduced and the level of anti-inflammatory cytokines is significantly increased in group 1, approaching to the normal values. In group 2, the level of proinflammatory cytokines decreases more than in group 1 after the treatment. The level of anti-inflammatory cytokines also increases more than in group 1 (high treatment efficiency). The intensity of the rate of decrease of PASI after treatment in patients of group 2 is at least 1.2 times higher than in I group, of DLQI after treatment in patients of group 2 is at least 1.44 times higher than in group 1. Conclusions. The registered changes in the serum of patients with moderate severity of papular-plaque form of psoriasis indicate their essential role in the pathogenesis of psoriasis.</p></abstract><trans-abstract xml:lang="ru"><p>Цель исследования - изучение роли некоторых провоспалительных и противовоспалительных цитокинов в патогенезе псориаза. Материал и методы. Были исследованы 110 больных среднетяжелыми формами папуло-бляшечного псориаза, которые были разделены на две группы: 65 больных (1-я группа), которым было назначено традиционное лечение (дезинтоксикационное, антиоксидантное, антигистаминное, мультивитаминное, мембраностабилизирующее, местное противовоспалительное) и 45 больных (2-я группа), которым было назначено альтернативное лечение (наряду с традиционной терапией получали гепатопротекторы). Группу контроля составили 18 практически здоровых людей. Степень тяжести псориатического процесса на коже (степень выраженности эритемы, инфильтрации, шелушения и распространенность процесса) оценивали по индексу PASI, качество жизни больных - по индексу DLQI, клиническую эффективность терапии - на основании динамики индексов PASI и DLQI до и после лечения. В сыворотке крови больных псориазом исследовали концентрации IFNγ, TNFα, IL-1α, IL-2, IL-10 и TGFb методом иммуноферментного количественного анализа. Результаты. В обеих группах больных псориазом до лечения установлено значимое увеличение показателей циркулирующих провоспалительных цитокинов и снижение показателей противовоспалительных цитокинов по сравнению с контролем. В 1-й группе больных показатели провоспалительных цитокинов после лечения значительно снижаются, а противовоспалительных цитокинов - повышаются, приближаясь к норме. Во 2-й группе больных показатели провоспалительных цитокинов после лечения снижаются больше, чем в 1-й группе, а содержание противовоспалительных цитокинов повышается больше, чем в 1-й группе (высокая эффективность лечения во 2-й группе). Интенсивность темпа снижения индекса PASI после лечения во 2-й группе больных минимум в 1,2 раза выше, чем в 1-й группе, индекса DLQI после лечения во 2-й группе больных минимум в 1,44 раза выше, чем в 1-й группе. Обсуждение. Изменения в сыворотке крови больных среднетяжелой формой папуло-бляшечного псориаза указывают на их существенную роль в патогенезе псориаза, эффективность лечения больных псориазом высокая при комплексном подходе.</p></trans-abstract><kwd-group xml:lang="en"><kwd>papular-plaque psoriasis</kwd><kwd>cytokines</kwd><kwd>interleukins</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>папуло-бляшечный псориаз</kwd><kwd>цитокины</kwd><kwd>интерлейкины</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Puig L., Julia A., Marsal S. The pathogenesis and genetics of psoriasis. Aclas Dermosifiliogr. 2014; 105(6): 535-45.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Mahil S.K., Capon F., Barker J.N. Genetics of psoriasis. Dermatol. Clin. 2015; 33(1): 1-11.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Lowes M.A., Lew W., Krueger J.G. Current concepts in the immunopathogenesis of psoriasis. Dermatol. Clin. 2004; 22(4): 349-69.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Gudjonsson J.E., Johnston A., Sigmundsdottir H., Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin. Exp. Immunol. 2004; 135(1): 1-8.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Kim J., Krueger J.G. The immunopathogenesis of psoriasis. Dermatol. Clin. 2015; 33(1): 13-23.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Global report on psoriasis. Accessed at: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Weigle N., McBane S. Psoriasis. Am. Fam. Physician. 2013; 87(9): 626-33.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Kimball A.B., Jacobson C., Weiss S., Vreeland M.G., Wu Y. The psychosocial burden of psoriasis. Am. J. Clin. Dermatol. 2005; 6(6): 383-92.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Krueger G., Koo J., Lebwohl M., Menter A., Stern R.S., Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. 2001; 137(3): 280-84.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Weiss S.C., Kimball A.B., Liewehr D.J., Blauvelt A., Turner M.L., Emanuel E.J. Quantifying the harmful effect of psoriasis on health-related quality of life. J. Am. Acad. Dermatol. 2002; 47(4): 512-18.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Akay A., Pekcanlar A., Bozdag K.E., Altintas L., Karaman A. Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J. Am. Acad. Dermatol. 2002; 16(4): 347-52.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Fortes C., Mastroeni S., Leffondre K., Sampogna F., Melchi F., Mazzotti E., et al. Relationship between smoking and the clinical severity of psoriasis. Arch. Dermatol. 2005; 141(12): 1580-84.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Fortune D.G., Main C.J., O’Sullivan T.M., Griffiths C.E. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br. J. Dermatol. 1997; 137(5): 755-60.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Kimball A.B., Leonardi C., Stahle M., Gulliver W., Chevrier M., Fakharzadeh S., et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, diseasebased registry (PSOLAR). Br. J. Dermatol. 2014; 171(1): 137-47.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Gelfand J.M., Troxel A.B., Lewis J.D., Kurd S.K., Shin D.B., Wang X., et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch. Dermatol. 2007; 143(12): 1493-99.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Arican O., Aral M., Sasmaz S., Ciragil P. Serum levels of TNFα, IFNγ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005; 2005(5): 273-9.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. Nature. 2007; 445(7130): 866-73.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Fuentes-Duculan J., Suarez-Farinas M., Zaba L.C., Nograles K.E., Pierson K.C., Mitsui H., et al. A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J. Invest. Dermatol. 2010; 130(10): 2412-22.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Nestle F., Kaplan D.H., Barker J.H. Psoriasis. N. Engl. J. Med. 2009; 361(5): 496-509.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J. Eur. Acad. Dermatol. Venereol. 2012; 26(Suppl. 2): 3-11.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Jadali Z., Izad M., Eslami M.B., Mansouri P., Safari R., Bayatian P., et al. Th1/Th2 cytokines in psoriasis. Iran J. Publ. Health. 2007; 36(2): 87-91.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Szegedi A., Aleksza M., Gonda A., Irinyi B., Sipka S., Hunyadi J., Antal-Szalmás P. Elevated rate of T-helper-1 lymphocytes and serum IFN-gamma levels in psoriatic patients. Immunol. Lett. 2003; 86(3): 277-80.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Coondoo A. The role of cytokines in the pathomechanism of cutaneous disorders. Indian J. Dermatol. 2012; 57(2): 90-6.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Furue M., Cadone T. “Inflammatory skin march” in atopic dermatitis and psoriasis. Inflamm. Res. 2017; 66(10): 833-42. doi: 10.1007/s00011-017-1065-z.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Курников Г.Ю., Шебашова Н.В., Копытова Т.В., Абалихина Е.П. Гепатотропные препараты в комплексном лечении больных псориазом. Экспериментальная и клиническая дерматокосметология. 2004; (3): 33-6.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Арчаков А.И., Сельцовский Ф.П., Лисов В.И., Цыганов Д.И., Княжев В.А., Ипатова О.М., Торховская Т.И. Фосфоглив: механизм действия и эффективность применения в клинике. Вопросы медицинской химии. 2002; 48(2): 139-53.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Menter A., Smith C., Barker J. Psoriasis. Oxford: Health Press; 2004.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Augustin M., Krüger K., Radtke M.A., Schwipp I., Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology. 2008; 216(4): 366-72.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Кубанов А.А., Карамова А.Э., Знаменская Л.Ф., Чикин В.В., Кондрашова В.В. Индекс PASI (Psoriasis Area and Severity Index) в оценке клинических проявлений псориаза. Вестник дерматологии и венерологии. 2016; (4): 33-8.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Адаскевич В.П. Диагностические индексы в дерматологии. М.: Издательство Панфилова; БИНОМ; 2014.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Mattei P.L., Corey K.C., Kimball A.B. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J. Eur. Acad. Dermatol. Venereol. 2014; 28(3): 333-7.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Hagg D., Sundstrom A., Eriksson M., Schmitt-Egenolf M. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI). J. Eur. Acad. Dermatol. Venereol. 2015; 29(3): 452-6.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Twiss J., Meads D.M., Preston E.P., Crawford S.R., McKenna S.P. Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis? J. Invest. Dermatol. 2012; 132(1): 76-84.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Vender R., Lynde C., Gilbert M., Ho V., Sapra S., Poulin-Costello M. Etanercept improves quality of life outcomes and treatment satisfaction in patients with moderate to severe plaque psoriasis in clinical practice. J. Cutan. Med. Surg. 2012; 16(6): 407-16.</mixed-citation></ref></ref-list></back></article>
